R&D News | pharmaphorum

News

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with

News

AHA: First data backs AskBio’s heart failure gene therapy

Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse event

News

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular

News

AHA: Wegovy improves survival in outcomes trial

Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are

News

UK start-up is planning pharma factory in space

A new UK company, called BioOrbit, has been formed with the aim of developing hardware for the manufacture of pharmaceuticals in space.

News

Bayer pledges up to $1.5bn for Recursion oncology alliance

Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cance

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AHA: First data backs AskBio’s heart failure gene therapy

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

AHA: Wegovy improves survival in outcomes trial

UK start-up is planning pharma factory in space

Bayer pledges up to $1.5bn for Recursion oncology alliance

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks